Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 13, 2025GeroScienceOpen Access

Recent advances in treating age-related macular degeneration and diabetic retinopathy: Current therapies and emerging novel approaches

View Full Paper
Ask AI
Bookmark
Share

Authors

RARéka AntalZBZoltán BenyóZNZoltán Zsolt Nagy

Discussion

Loading...

Member takes

Overview

This review highlights current therapies for neovascular age-related macular degeneration and proliferative diabetic retinopathy, suggesting novel approaches may reduce reliance on anti-VEGF injections.

Key Points

  • Novel therapies for retinopathies may eliminate the need for intravitreal injections of anti-VEGF, improving patient outcomes.
  • Meta-analysis of human clinical trials indicates efficient treatments targeting vascular endothelial growth factor, but with potential adverse events.
  • Emerging gene therapy-based products and small-molecule tyrosine kinase inhibitors present promising alternatives to current strategies.
  • Different administration routes for TKIs have been tested, revealing varying safety and efficacy profiles that warrant further exploration.

Cite This Study

Antal et al. (2025) studied this question.

synapsesocial.com/papers/68ed1896f29694dd1da78a55https://doi.org/10.1007/s11357-025-01921-1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Therapeutic strategies targeting ocular vasculopathies: Current advances and emerging challenges2025
  2. 2Revolutionizing age-related macular degeneration treatment: Advances and future directions in non-invasive retinal drug delivery systems2025
  3. 3Diabetic Retinopathy in Focus: Update on Treatment Advances, Pharmaceutical Approaches, and New Technologies2025
  4. 4THE ROLE OF ANTI-VEGF THERAPY IN THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION: A COMPARATIVE ANALYSIS OF DRUG EFFICACY2025
  5. 5Drug Delivery Technologies for the Treatment of Age‐Related Macular Degeneration2025